Suchen
Capricor Therapeutics Inc
CAPRZur Watchlist hinzufügen
23.210USD
+0.140+0.61%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
1.34BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Capricor Therapeutics Inc Unternehmen
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. It leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.
Capricor Therapeutics Inc Informationen
BörsenkürzelCAPR
Name des UnternehmensCapricor Therapeutics Inc
IPO-datumJun 04, 2002
CEOMarban (Linda)
Anzahl der mitarbeiter160
WertpapierartOrdinary Share
GeschäftsjahresendeJun 04
Addresse10865 Road to the Cure
StadtSAN DIEGO
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl92121
Telefon13103583200
Websitehttps://capricor.com/
BörsenkürzelCAPR
IPO-datumJun 04, 2002
CEOMarban (Linda)
Führungskräfte von Capricor Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Linda Marban, Ph.D.
Dr. Linda Marban, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
212.02K
--
Mr. David B. Musket
Mr. David B. Musket
Independent Director
Independent Director
88.79K
--
Mr. Anthony Bergmann
Mr. Anthony Bergmann
Chief Financial Officer
Chief Financial Officer
11.22K
--
Dr. Frank I. Litvack, M.D.
Dr. Frank I. Litvack, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Ms. Karen G. Krasney, J.D.
Ms. Karen G. Krasney, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
--
--
Mr. George W. Dunbar, Jr.
Mr. George W. Dunbar, Jr.
Independent Director
Independent Director
--
--
Ms. Karimah Es Sabar
Ms. Karimah Es Sabar
Independent Director
Independent Director
--
--
Dr. Paul Auwaerter, M.D.
Dr. Paul Auwaerter, M.D.
Independent Director
Independent Director
--
--
Dr. Philip J. (Phil) Gotwals, Ph.D.
Dr. Philip J. (Phil) Gotwals, Ph.D.
Independent Director
Independent Director
--
--
Mr. Michael Kelliher
Mr. Michael Kelliher
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Linda Marban, Ph.D.
Dr. Linda Marban, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
212.02K
--
Mr. David B. Musket
Mr. David B. Musket
Independent Director
Independent Director
88.79K
--
Mr. Anthony Bergmann
Mr. Anthony Bergmann
Chief Financial Officer
Chief Financial Officer
11.22K
--
Dr. Frank I. Litvack, M.D.
Dr. Frank I. Litvack, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Ms. Karen G. Krasney, J.D.
Ms. Karen G. Krasney, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
--
--
Mr. George W. Dunbar, Jr.
Mr. George W. Dunbar, Jr.
Independent Director
Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Capricor Therapeutics Inc?
Die fünf größten Anteilseigner von Capricor Therapeutics Inc sind: Dr. Linda Marban, Ph.D.
Wie viele Institutionen halten Anteile an Capricor Therapeutics Inc (CAPR)?
Mit Stand vom 2026Q1 halten 325 Institutionen Anteile an Capricor Therapeutics Inc, mit einem Gesamtmarktwert von etwa 31.81M, was 54.99% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 10164129.00 gestiegen.